本文選題：多形性膠質(zhì)母細(xì)胞瘤　切入點(diǎn)：嵌合抗原受體T細(xì)胞　出處：《中國(guó)腫瘤臨床》2017年16期

【摘要】：多形性膠質(zhì)母細(xì)胞瘤(glioblastoma multiforme,GBM)是惡性程度最高的腦膠質(zhì)瘤,傳統(tǒng)手術(shù)結(jié)合放、化療療效有限。嵌合抗原受體是由單一分子組成的抗原重組受體,重新定向T細(xì)胞的特異性和功能,由CD28或4-1BB構(gòu)成的第二代CAR-T能識(shí)別抗原,完全活化T細(xì)胞并增強(qiáng)T細(xì)胞功能和持久性,是新興GBM療法的關(guān)注焦點(diǎn)。本文從CAR-T研究現(xiàn)狀出發(fā),主要介紹其發(fā)展歷程和GBM相關(guān)的有效靶點(diǎn),綜述其理論基礎(chǔ),著重以白介素13受體α2、表皮生長(zhǎng)因子受體變異Ⅶ、人表皮生長(zhǎng)因子受體2和酪氨酸蛋白激酶受體A2這四種膠質(zhì)瘤相關(guān)抗原為例,探討靶點(diǎn)的結(jié)構(gòu)、功能特性、前期研究和臨床研究前景。選擇性表達(dá)在GBM的白介素13受體α2在臨床Ⅰ期治療復(fù)發(fā)性GBM是安全有效的;表皮生長(zhǎng)因子受體變異Ⅷ只存在于癌細(xì)胞和膠質(zhì)母細(xì)胞瘤干細(xì)胞,與預(yù)后不良密切相關(guān),正在進(jìn)行Ⅰ、Ⅱ期臨床試驗(yàn);表皮生長(zhǎng)因子受體2和酪氨酸蛋白激酶受體A也取得重大進(jìn)展。這些特異性CAR-T可能成為治療相應(yīng)靶向陽性的GBM的重要免疫療法。本文集中總結(jié)了目前CAR-T治療GBM的應(yīng)用價(jià)值及挑戰(zhàn)。
[Abstract]:Glioblastoma multiforme GBM (glioblastoma multiforme GBM) is the most malignant glioma with limited curative effect of conventional surgery combined with radiotherapy and chemotherapy. Chimeric antigen receptor is a recombinant antigen receptor composed of a single molecule, which redirects the specificity and function of T cells. The second generation CAR-T composed of CD28 or 4-1BB can recognize antigens, activate T cells and enhance the function and persistence of T cells, which is the focus of new GBM therapy. This paper mainly introduces its development process and effective targets related to GBM, and summarizes its theoretical basis, focusing on interleukin-13 receptor 偽 _ 2, epidermal growth factor receptor variation 鈪，

本文編號(hào)：1665103